- Conditions
- Cardiac Pacing, Right Ventricular Pacing, Left Ventricular Ejection Fraction
- Interventions
- Medtronic or Vitatron Dual-Chamber Pacemaker, Medtronic SelectSecure 3830 Lead
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 10
- States / cities
- Des Moines, Iowa • Silver Spring, Maryland • Southfield, Michigan + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart; Functional Disturbance
- Interventions
- Not listed
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Heart Failure, Reduced Ejection Fraction
- Interventions
- sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 23
- States / cities
- Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more
- Conditions
- Left Ventricular Ejection Fraction, Heart Failure (HF), Left Bundle-Branch Block
- Interventions
- LB-CRT, BIV-CRT
- Device
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- Not listed
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Falls Church, Virginia
- Conditions
- Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction
- Interventions
- Levosimendan
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 9
- States / cities
- Stanford, California • Chicago, Illinois • Minneapolis, Minnesota + 6 more
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Interventions
- Levosimendan, Matching Placebo
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 16
- States / cities
- Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more
- Conditions
- Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
- Interventions
- Dobutamine, Amlodipine
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Left Ventricular Dysfunction, Ventricular Dysfunction, Heart Diseases, Cardiovascular Diseases
- Interventions
- Use of Eko DUO electronic Stethoscope
- Device
- Lead sponsor
- Eko Devices, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI
- Interventions
- Prophylactic Impella support for a non-emergent PCI
- Device
- Lead sponsor
- Abiomed Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 18 more
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- mavacamten, Placebo
- Drug
- Lead sponsor
- MyoKardia, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 32
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 28 more
- Conditions
- Heart Failure, Systolic
- Interventions
- Sacubitril/Valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Heart Failure
- Interventions
- vicadrostat, empagliflozin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 103
- States / cities
- Montgomery, Alabama • Beverly Hills, California • Covina, California + 88 more
- Conditions
- Transthoracic Echocardiography, Suspected or Known Structural or Functional Cardiac Abnormality
- Interventions
- Optison
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Los Angeles, California • Augusta, Georgia + 5 more
- Conditions
- Cardiac Disease
- Interventions
- DEFINITY®
- Drug
- Lead sponsor
- Lantheus Medical Imaging
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 12 more
- Conditions
- Asymptomatic Left Ventricular Systolic Dysfunction (Disorder), Heart Failure
- Interventions
- AI-enabled ECG-based Screening Tool
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Heart Failure
- Interventions
- LCZ696, Valsartan, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more
- Conditions
- Pediatric Heart Failure
- Interventions
- LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 25
- States / cities
- Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram
- Interventions
- Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Costa Mesa, California • Fresno, California + 34 more
- Conditions
- Ventricular Ejection Fraction
- Interventions
- Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
- Drug
- Lead sponsor
- Lantheus Medical Imaging
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Chicago, Illinois • Washington DC, Maryland + 7 more
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
- Interventions
- Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Left Ventricular Dysfunction
- Interventions
- Adult stem cells, Placebo
- Biological
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
- Conditions
- Prior Acute Myocardial Infarction, Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l), Reduced Left Ventricle Ejection Fraction (<50%), Symptoms of Heart Failure (NYHA Class II-III)
- Interventions
- Cardiopulmonary exercise test, Echocardiogram
- Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Hypertension, Pulmonary, Heart Failure With Reduced Ejection Fraction
- Interventions
- Eko CORE 500 Digital Stethoscope
- Device
- Lead sponsor
- Eko Devices, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,850 participants
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- O'Fallon, Illinois • Springfield, Illinois • Norfolk, Virginia
- Conditions
- Ventricular Ejection Fraction
- Interventions
- Anumana Low EF AI-ECG Algorithm, Care-as-Usual
- Device · Other
- Lead sponsor
- Anumana, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11,610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more